Theriva Biologics, Inc. Updates Stock Incentive Plan and Articles of IncorporationWASHINGTON, D.C. – October 31, 2024 – Theriva Biologics, Inc. (NYSEAMERICAN: SYN) held its 2024 Annual Meeting of Stockholders on October 31, 2024. During the

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Synthetic Biologics’s 8K filing here.

About Synthetic Biologics

Synthetic Biologics, Inc, a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases.